QP Pharmachem asked to stop manufacturing after samples found to be of non-standard quality: Govt

New Delhi: A Punjab-based drugmaker was asked to stop all manufacturing activities after samples collected from its premises, following an alert by the WHO, were found to be "not of standard quality", the Lok Sabha was informed on Friday. Minister of State for Health Bharati Pravin Pawar, in a written reply in the Lower House of Parliament, said the World Health Organization (WHO) issued a medical product alert for a batch of India-made Guaifenesin syrup in the Marshall Islands and the Federated States of Micronesia.

Read also: Manufacturing licences of QP Pharmachem, 2 others suspended

Medical Dialogues team had reported that the Drug Controller General of India (DCGI) had notified all drug manufacturers' associations and exporters not to submit the same batch of cough syrup to more than one laboratory at a time, as this practice is highly objectionable and not acceptable from a regulatory standpoint.

Read also: Do not submit same batch no. of cough syrup to two different laboratories: DCGI tells Manufacturers, Exporters